FibroGen Inc. $(FGEN)$ has released its financial results for the second quarter of 2025, revealing significant developments in its business operations. The company reported $23.5 million in cash, cash equivalents, and accounts receivable in the U.S., and a total of $142.1 million in consolidated cash, cash equivalents, and accounts receivable. A major highlight of the quarter is the announced sale of FibroGen China to AstraZeneca, expected to bring a total consideration of approximately $210 million, marking a $50 million increase from initial guidance. This transaction, anticipated to close in the third quarter of 2025, comprises an enterprise value of $85 million and estimated net cash held in China of approximately $125 million. Upon closing, FibroGen plans to repay its term loan to Morgan Stanley Tactical Value, which will simplify the company's capital structure. Additionally, FibroGen maintains its rights to roxadustat in the U.S. and all markets outside of China, South Korea, and those licensed to Astellas. The company has also appointed Michael Kauffman, M.D., Ph.D., to its Board of Directors. Looking ahead, the company expects its cash, cash equivalents, and accounts receivable to be sufficient to fund operating plans into 2028 following the closure of the FibroGen China sale. Notably, FibroGen is set to initiate a Phase 2 monotherapy trial of FG-3246 for metastatic castration-resistant prostate cancer in the third quarter of 2025 and has reached an agreement with the FDA on the pivotal Phase 3 trial design for roxadustat for anemia treatment in patients with lower-risk myelodysplastic syndromes.